Levetiracetam Tablet, Film Coated, Extended Release
Product Images NDC 60429-349

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 60429-349). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

60429 349 60lb Levetiracetam 500mg Er Tabs

Levetiracetam Extended-Release 500 mg tablets label, showing 60 tablets per bottle. The label includes the NDC 60429-349-60 and highlights once daily dosing. The product is identified as film-coated, extended-release tablets and is labeled for prescription use only by Golden State Medical Supply, Inc. Manufacturer information and storage instructions are also present.*

FDA Label Image

60429 350 60lb Levetiracetam 750 mg Er Tabs

Label for Levetiracetam Extended-Release Tablets 750 mg by Golden State Medical Supply, Inc. The label includes NDC 60429-350-60, a barcode, and states 60 tablets with once daily dosing. Storage instructions and manufacturing details are partially visible on the label.*

FDA Label Image

Fig1.jpg (Fig1)

A bar chart comparing the percentage of patients across three groups: placebo (7.4%), immediate-release levetiracetam tablets 1000 mg/day (37.1%), and immediate-release levetiracetam tablets 3000 mg/day (39.6%). The chart indicates statistically significant differences versus placebo for the two active treatment groups.*

FDA Label Image

Fig2.jpg (Fig2)

A bar graph comparing the percentage of patients across three groups: placebo, immediate-release levetiracetam tablets 1000 mg/day, and immediate-release levetiracetam tablets 2000 mg/day. The graph indicates statistical significance for the 2000 mg/day group versus placebo, with percentages approximately 6.3%, 20.8%, and 35.2%, respectively, on the y-axis representing percent of patients.*

FDA Label Image

Fig3.jpg (Fig3)

A bar chart displaying the percentage of patients for two groups: Placebo (N=104) with 14.4% and Immediate-release levetiracetam tablets 3000 mg/day (N=180) with 39.4%. A note indicates statistical significance of the immediate-release levetiracetam group versus placebo.*

FDA Label Image

Fig4.jpg (Fig4)

Bar chart comparing the percentage of patients between placebo (N=97) and immediate-release levetiracetam tablets (N=101). The placebo group shows 19.6%, while the immediate-release levetiracetam group shows 44.6%, with a notation indicating statistical significance versus placebo.*

FDA Label Image

Levetiracetamxr-01 (Levetiracetam Xr 01)

Chemical structure of the active ingredient Levetiracetam, shown as a molecular diagram with standard atomic abbreviations and bonds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.